US9943526 — Optimizing mifepristone levels for cushing's patients
Method of Use · Assigned to Corcept Therapeutics Inc · Expires 2036-04-20 · 10y remaining
What this patent protects
This patent protects a method for optimizing mifepristone levels in patients with Cushing's syndrome by adjusting daily doses based on serum level testing.
USPTO Abstract
The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
Drugs covered by this patent
- Mifeprex (MIFEPRISTONE) · Corcept Therap
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1643 |
— | Mifeprex |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.